Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Protecting Cancer Patients Against COVID-19: Beyond Vaccines, One Year from Vaccine Approvals

ESMO-Webinar-Series-Protecting-Cancer-Patients-1000x250-Beyond-Vaccines
Live on
06 Apr 2022 at 18:30 CEST

It is with great pleasure that I invite you to participate in the third webinar of a new ESMO short series: Protecting Cancer Patients against COVID-19, which will focus on new therapeutic strategies beyond vaccines to prevent morbidity and mortality from COVID-19 in patients with cancer.

This webinar is developed with the aim to provide an overview of how to protect patients with cancer from viral pathogens. It will highlight novel anti-SARS-CoV-2 monoclonal antibodies and oral SARS-CoV-2 antiretrovirals to prevent COVID-19 related morbidity and mortality with an emphasis on their role in patients with cancer.

We will begin with a lecture on lessons learnt before COVID-19 pandemic on protecting patients with cancer from viral pathogens. This will be followed by an elaboration on prevention of COVID-19 related morbidity and mortality by administration of novel monoclonal antibodies and their impact on patients with cancer. Finally, we will evaluate the prevention of COVID-19 related morbidity and mortality by administration of novel oral, specific antiretroviral drugs with an emphasis on how to position their administration in patients with cancer.

The programme is designed to provide an overview of the current evidence, offer expert opinion exchange and provide some important considerations with regard to new specific therapeutics one year from first vaccine approvals. I strongly encourage and invite you to register and join us all in this new ESMO activity.

Dr. Christina Ruhlmann
Department of Oncology, Odense University Hospital
Odense, Denmark

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Christina Ruhlmann

15 min

Protecting patients with cancer from viral pathogens, beyond vaccines: lessons learnt in the pre-COVID era

Nicola Giesen

20 min

Beyond vaccines: can monoclonal antibodies prevent COVID-related morbidity/mortality and how do we position patients with cancer?

Marek Trněný

15 min

Beyond vaccines: can oral SARS-CoV-2 antiretrovirals prevent COVID-related morbidity/mortality and how do we position patients with cancer?

Brigitte Autran

15 min

LIVE Q&A

All

A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event.

Learning objectives:

  • To provide an overview on how to protect patients with cancer from viral pathogens
  • To highlight therapeutic interventions beyond vaccines, such as new anti-SARS-CoV-2 monoclonal antibodies for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients
  • To highlight therapeutic interventions beyond vaccines, such as new SARS-CoV-2 antiretrovirals for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.